Last week, we published our latest update on rare cases of heart inflammation that have been linked to the mRNA COVID jabs, including the jabs from Pfizer-BioNTech and Moderna. After a hurried secret meeting with its advisory board on vaccine safety, the FDA reluctantly release a warning asking patients experiencing these symptoms to seek help immediately.

The latest study, published in JAMA's Cardiology Journal on Tuesday, showed that 23 male soldiers (including 22 who were deemed "previously health") between the ages of 20 and 51 presented "acute onset of marked chest pain" within four days of receiving their second dose. Patients who sought care for chest pain in the military health-care system following COVID-19 vaccination and were subsequently diagnosed with clinical myocarditis were included in the case study.

All the members who tested for myocarditis (for those who aren't familiar with it, myocarditis is a condition that causes the swelling of the heart muscle and can cause difficulty breathing, heart failure, and death) were all "physically fit by military standards and lacking any known history of cardiac disease, significant cardiac risk factors, or exposure to cardiotoxic agents."

All of the patients whose data was included in the study underwent electrocardiography and echocardiography tests. Abnormal electrocardiography findings were recorded in 19 patients (83%): findings included ST-segment elevations, T-wave inversions, and nonspecific ST changes. Echocardiography in 4 patients (17%) demonstrated reduced left ventricular ejection fractions (40% to 50%).

The cardiac symptoms faded within a week of onset for 16 patients, while 7 others continued to have chest discomfort at the time of this report; follow-up is ongoing.